MIT Develops Durable Injectable Gels - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

MIT Develops Durable Injectable Gels

Shear-thinning hydrogels can be injected into the body to carry drugs or cells to regenerate damaged tissue, but these hydrogels are vulnerable to degradation by mechanical stresses. Chemical engineers at the Massachusetts Institute of Technology (MIT) developed a gel that is made durable by a polymeric reinforcing network, which is activated when the gel is heated to body temperature (37 °C).

The research team, led by Bradley Olsen, an assistant professor of chemical engineering at MIT, worked with a protein hydrogel that consisted of loosely packed proteins held together by links between protein segments. Polymers attached to the ends of each protein are soluble in water and float freely in the gel at lower temperatures. When heated to body temperature, however, the polymers become insoluble, separate out of solution, and join together to form a reinforcing grid within the gel.

The researchers found that gels with this reinforcing network were significantly stiffer and much slower to degrade when exposed to mechanical stress. This offers a promising way to thwart the tendency of shear thinning materials to erode once in the body, said Jason Burdick, an associate professor of bioengineering at the University of Pennsylvania, in the MIT press release.

The gels can also be tuned to degrade over time, which would be useful for long-term drug release. The researchers are now working on ways to control this feature, as well as incorporating different types of biological functions into the gels, according to the release.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here